Home Stock

Stock Research: NovoCure

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

NovoCure

NSQ:NVCR JE00BYSS4X48
22
  • Value
    32
  • Growth
    26
  • Safety
    Safety
    31
  • Combined
    10
  • Sentiment
    60
  • 360° View
    360° View
    22
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

NovoCure Limited is a global oncology company developing Tumor Treating Fields (TTFields) devices. The company operates in the medical device industry. It operates globally, with a license to market Optune in China, Hong Kong, Macau, and Taiwan. In the last fiscal year, the company had a market cap of $1,887 million, profits of $468 million, and revenue of $605 million, with 1488 employees.

more
Strongest Rank Dividend Yield
Weakest Rank Capital Growth
Country Jersey
Industry Health Care Equipment
Size Medium
Website novocure.com
Index
NASDAQ
D.J. US Medical Equipment
NovoCure stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 20 27 11
Growth
26 80 19 55
Safety
Safety
31 7 25 12
Sentiment
60 30 1 10
360° View
360° View
22 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
61 51 28 3
Opinions Change
37 40 9 26
Pro Holdings
n/a 23 6 72
Market Pulse
64 63 12 38
Sentiment
60 30 1 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
32 20 27 11
Growth
26 80 19 55
Safety Safety
31 7 25 12
Combined
10 17 6 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
58 27 46 3
Price vs. Earnings (P/E)
4 4 4 4
Price vs. Book (P/B)
29 11 28 12
Dividend Yield
1 1 1 1
Value
32 20 27 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
16 1 33 52
Profit Growth
39 74 6 52
Capital Growth
96 100 98 90
Stock Returns
9 84 3 7
Growth
26 80 19 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
16 1 6 12
Refinancing
85 62 93 67
Liquidity
16 7 8 4
Safety Safety
31 7 25 12

Similar Stocks

Discover high‑ranked alternatives to NovoCure and broaden your portfolio horizons.

STMicroelectronics

PAR:STMPA
Country: Netherlands
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Drägerwerk

GER:DRW8
Country: Germany
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Opera

NSQ:OPRA
Country: Norway
Industry: Application Software
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews